Maridea Wealth Management LLC Invests $551,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Maridea Wealth Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 4,533 shares of the biotechnology company's stock, valued at approximately $551,000.

Other large investors have also modified their holdings of the company. Louisiana State Employees Retirement System raised its position in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after acquiring an additional 100 shares in the last quarter. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 138 shares in the last quarter. CIBC Asset Management Inc lifted its stake in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock valued at $347,000 after purchasing an additional 139 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after buying an additional 145 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $6.59 during trading hours on Monday, hitting $63.82. The stock had a trading volume of 4,633,758 shares, compared to its average volume of 1,270,114. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 1-year low of $62.53 and a 1-year high of $173.25. The stock's fifty day simple moving average is $102.66 and its 200 day simple moving average is $115.90. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 51.06 and a beta of 0.79.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright restated a "sell" rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Finally, Royal Bank of Canada downgraded Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price objective for the stock from $161.00 to $87.00 in a research report on Monday. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $164.05.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.